SCHEDULE: Silence Therapeutics Plc: Griffiths Group Sells ADSs

Richard Griffiths and associated entities report a significant sale of Silence Therapeutics Plc ADSs, reducing their beneficial ownership.

Summary

• Richard Griffiths and associated entities have filed an amendment to their Schedule 13D, reporting transactions related to Silence Therapeutics Plc's Ordinary Shares.
• The filing reflects open market transactions of the Issuer's ADSs by the Reporting Person and dilution due to an increase in the Issuer's share capital.
• Richard Griffiths sold an aggregate of 1,544,374 ADSs in open market transactions between June 29, 2026, and July 6, 2026, for total proceeds of $16.3 million.
• Ora Capital Limited holds 19,155,522 ordinary shares represented by ADSs, constituting 13.5% of the class.
• Richard Griffiths, as a whole, beneficially owns 30,844,458 ordinary shares represented by ADSs, accounting for 21.7% of the class.
• This percentage is calculated based on 141,701,847 outstanding ordinary shares of the Issuer as disclosed in the Issuer's last SEC filing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant sale of shares by a major beneficial owner, which could signal a lack of confidence or a strategic shift.

Negatives

• Significant sale of ADSs by Richard Griffiths and associated entities, reducing their beneficial ownership stake in Silence Therapeutics Plc.

Risks

• Dilution as a result of an increase in the share capital of the Issuer.

Future Outlook

The filing primarily reports past transactions and does not contain explicit forward-looking statements or guidance regarding future performance or strategy.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes in publicly traded companies, often indicating shifts in investor sentiment or strategy. This filing details a reduction in beneficial ownership by a key individual and associated entities within the biotechnology sector.

Stakeholder Impact

• Shareholders may be impacted by the reduction in beneficial ownership by Richard Griffiths and associated entities, potentially affecting market perception and share price due to decreased insider support or strategic alignment.

Next Steps

• The filing indicates that the Schedule 13D remains in full force and effect, subject to further amendments as required by law.

Key Dates

Recommendation

The filing details a reduction in beneficial ownership by a significant stakeholder, which is a negative signal. However, without further context on the reasons for the sale or the company's overall financial health and prospects, a 'hold' recommendation is prudent, suggesting investors monitor the situation for further developments.

Keywords

Schedule 13D, Silence Therapeutics Plc, Richard Griffiths, Ora Capital Limited, ADSs, Ordinary Shares, Beneficial Ownership, SEC Filing, Open Market Transactions